Fortune 50 Pharmaceutical Company Defeats Class Certification

In a significant victory for a Fortune 50 pharmaceutical company, the 3rd U.S. Circuit Court of Appeals vacated the trial court's class certification order following a nationwide class action alleging the company fixed the price of blood reagents. Our firm represented the pharmaceutical company in the litigation.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.